menu
    • menu
    [{"orgOrder":0,"company":"Faes Farma","sponsor":"SIFI","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"Polyhexanide","moa":"Cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Faes Farma \/ Faes Farma","highestDevelopmentStatusID":"15","companyTruncated":"Faes Farma \/ Faes Farma"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faes Farma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Faes Farma \/ Undisclosed"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Dynamic Science","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Faes Farma \/ Dynamic Science","highestDevelopmentStatusID":"10","companyTruncated":"Faes Farma \/ Dynamic Science"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Dynamic Science","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Faes Farma \/ Dynamic Science","highestDevelopmentStatusID":"10","companyTruncated":"Faes Farma \/ Dynamic Science"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Faes Farma \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Faes Farma \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Agreement","leadProduct":"Potassium Chloride","moa":"||Solute carrier family 12 member 1 (SLC12A1)","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faes Farma \/ Faes Farma","highestDevelopmentStatusID":"15","companyTruncated":"Faes Farma \/ Faes Farma"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Faes Farma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Faes Farma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Faes Farma

    Menu

    Faes Farma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Recipient : SIFI

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            SIFI Merges into Faes Farma to Expand International Access to its Portfolio and Pipeline

                            Details : The Group will invest into the further development of Akantior (polihexanide) into existing and new geographies, as well as the development of polihexanide into additional orphan indications.

                            Product Name : Akantior

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 10, 2025

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Recipient : SIFI

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.

                            Details : Mesalazine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 19, 2023

                            Lead Product(s) : Mesalazine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Dynamic Science

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemo...

                            Details : Hydrocortisone is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemorrhoids.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            March 29, 2023

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Dynamic Science

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Hikma and FAES Farma Enter Into Exclusive Licensing Agreement for The Commercialisation of Bilastine Tablets I...

                            Details : Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercialisation of the product in the US following approval.

                            Product Name : Bilaxten

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 20, 2021

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Dynamic Science

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children

                            Details : Bilastine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 23, 2021

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Dynamic Science

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency

                            Details : Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Vitamin D Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            February 03, 2021

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Potassium Chloride,Ascorbic Acid,Sodium Chloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Recipient : Norgine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Norgine B.V. Inks Exclusive Licence and Distribution deal for PLENVU

                            Details : Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            February 12, 2020

                            Lead Product(s) : Potassium Chloride,Ascorbic Acid,Sodium Chloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Recipient : Norgine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Ora, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Mod...

                            Details : Bilastine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 27, 2018

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Ora, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Ora, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

                            Details : Bilastine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 27, 2017

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Ora, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Recipient : Charite University, Berlin, Germany

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bilastine Updosing - Characterization of Underlying Mechanisms

                            Details : Bilastine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Urticaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 06, 2011

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Charite University, Berlin, Germany

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth